Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality: Original Article

Journal of Internal Medicine

Volumn 268, Issue 4, 2010, Pages 348-358

  Parish, S ^a   Offer, A ^a   Thompson, A ^a   Link, E ^a   Di Angelantonio, E ^a   Bowman, L ^a   Armitage, J ^a   Danesh, J ^a   Collins, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

biomarker; cardiovascular disease; lipoprotein associated phospholipase A2; risk factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; LIPID; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULAR DISEASE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 77956306449     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02258.x     Document Type: Article

References (31)

1. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990 265 : 9682 9687.
2. Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006 26 : 2523 2529.
3. Rosenson RS. Lp-PLA2 and risk of atherosclerotic vascular disease. Lancet 2010 375 : 1498 1500.
4. Stafforini DM, Tjoelker LW, McCormick SP et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999 274 : 7018 7024.
5. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005 25 : 923 931.
6. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997 27 : 595 602.
7. MacPhee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999 338 (Pt 2 479 487.
8. Tjoelker LW, Wilder C, Eberhardt C et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995 374 : 549 553.
9. US Food and Drug Administration. URL http://www.accessdata.fda.gov/cdrh- docs/pdf5/K050523.pdf [accessed on 16 June 2010).
10. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY) URL http://clinicaltrials.gov/ct2/show/NCT00799903 [accessed on 16 June 2010].
11. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007 82 : 159 165.
12. van Vark LC, Kardys I, Bleumink GS et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006 27 : 2346 2352.
13. Gerber Y, Dunlay SM, Jaffe AS et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis 2009 203 : 593 598.
14. Suzuki T, Solomon C, Jenny NS et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail 2009 2 : 429 436.
15. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
16. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999 20 : 725 741.
17. MRC/BHF Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007 49 : 311 319.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
19. Plummer M. Improved estimates of floating absolute risk. Stat Med 2004 23 : 93 104.
20. Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 375 : 1536 1544.
21. Clarke R, Emberson JR, Parish S et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 2007 167 : 1373 1378.
22. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 : 1993 2000.
23. Clarke R, Shipley M, Lewington S et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999 150 : 341 353.
24. Shimokata K, Yamada Y, Kondo T et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 2004 172 : 167 173.
25. Yamada Y, Matsuo H, Segawa T et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost 2006 96 : 220 227.
26. Hou L, Chen S, Yu H et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009 125 : 11 20.
27. Jang Y, Kim OY, Koh SJ et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006 91 : 3521 3527.
28. Mohler ER 3rd., Ballantyne CM, Davidson MH et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008 51 : 1632 1641.
29. Serruys PW, Garcia-Garcia HM, Buszman P et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008 118 : 1172 1182.
30. Wilensky RL, Shi Y, Mohler ER 3rd. et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008 14 : 1059 1066.
31. The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). URL http://clinicaltrials.gov/ct2/show/ NCT01000727 [accessed on 16 June 2010].